Market Outlook

By 2035, the U.S. Ophthalmic Surgical Devices Market is expected to reach approximately USD 14.25 billion, expanding at a CAGR of 7.35% during the forecast period 2026–2035. The market is estimated at USD 7.01 billion in 2025, with historical analysis covering 2021 to 2024. Values in this report are expressed in USD billions.

The U.S. ophthalmic surgical devices industry occupies a strategically important position within medical technology because ophthalmic surgery combines exceptionally high procedure volumes with a rapidly aging population, established Medicare coverage, strong ambulatory surgery center penetration, recurring disposable-device utilization, and sustained innovation in intraocular lenses, glaucoma implants, vitreoretinal systems, phacoemulsification platforms, and laser-based procedures. The market is increasingly shaped not only by the number of surgical procedures performed but by the value of technology deployed per procedure.

Cataract surgery remains the economic foundation of the industry. U.S. cataract procedures are estimated to have approached 5.1 million procedures in 2025, with procedure volumes expected to rise toward approximately 5.9 million by 2030. This creates a recurring demand base for intraocular lenses, phacoemulsification consumables, fluidics packs, injector systems, ophthalmic viscoelastic devices, surgical blades, handpieces, irrigation and aspiration components, and related accessories.

Demographics provide a durable demand foundation. The U.S. population aged 65 years and older reached approximately 61.2 million in 2024, representing about 18% of the population, while the number of older adults increased 13% between 2020 and 2024. Because cataract, glaucoma, retinal disorders, and several corneal conditions are strongly associated with age, the expanding elderly population is directly increasing the addressable pool for ophthalmic surgery.

The market expanded from an estimated USD 5.31 billion in 2021 to USD 6.56 billion in 2024, supported by normalization of elective surgical volumes following pandemic-era disruptions, accelerated ambulatory procedure migration, rising adoption of premium intraocular lenses, greater utilization of minimally invasive glaucoma surgery, increased vitreoretinal procedure intensity, and capital replacement across ophthalmic surgery centers. The market reached approximately USD 7.01 billion in 2025 as procedure growth became increasingly supplemented by higher device value per case.

The forecast assumes continued expansion to approximately USD 7.53 billion in 2026, USD 9.99 billion by 2030, and USD 14.25 billion by 2035. Growth is expected to be strongest in premium cataract technology, presbyopia-correcting and toric IOLs, minimally invasive glaucoma devices, small-gauge vitreoretinal platforms, digital surgical guidance, advanced fluidics, preloaded delivery systems, and technologies that improve operating-room throughput.

The central commercial change in ophthalmic surgery is that U.S. providers are moving from purchasing individual devices toward purchasing integrated procedural ecosystems. An ophthalmic ASC increasingly evaluates the phaco platform, microscope or visualization workflow, IOL portfolio, disposable pack, injector, biometry compatibility, service contract, surgeon training, inventory management, and procedural throughput together. Manufacturers capable of influencing multiple parts of that workflow have substantially greater contracting leverage than suppliers competing in isolated categories.

The market estimates in this report reflect an ophthalmic surgical-device scope covering implantable lenses and glaucoma devices, phacoemulsification and vitreoretinal platforms, ophthalmic lasers, surgical visualization and guidance technologies directly associated with procedures, reusable instruments, single-use instruments, OVDs, procedure packs, handpieces, tubing, injectors, cutters, probes, and associated surgical accessories. Diagnostic-only imaging systems, routine vision-correction products, contact lenses, spectacles, and pharmaceutical-only treatments are excluded.

 

Introduction

According to the U.S. Ophthalmic Surgical Devices Market Report, ophthalmic surgery is becoming one of the most technology-intensive outpatient surgical specialties in the United States. Unlike many surgical markets that depend primarily on inpatient hospital capital budgets, ophthalmology benefits from a mature network of physician-owned and corporate-affiliated ambulatory surgery centers, hospital outpatient departments, academic eye institutes, specialty ophthalmology practices, and high-volume cataract centers.

The outpatient structure is economically important. Approximately 6,400 ASCs treated 3.4 million fee-for-service Medicare beneficiaries during 2024, with total Medicare program and beneficiary ASC spending reaching approximately USD 7.5 billion. Ophthalmology represented approximately 1,162 single-specialty ASCs in 2024, equivalent to about 20% of ASCs billing Medicare and making ophthalmology one of the largest dedicated ASC specialties nationally.

This infrastructure supports a purchasing environment very different from conventional hospital medtech procurement. High-volume ophthalmic surgery centers focus intensely on procedure minutes, room turnover, disposable cost per case, surgeon preference, IOL inventory, service reliability, equipment uptime, staff training requirements, waste reduction, and reimbursement. A modest improvement in operating-room efficiency can have significant economic value when multiplied across thousands of cataract cases each year.

Disease prevalence strengthens this demand base. CDC estimates indicate that approximately 4.22 million Americans were living with glaucoma in 2022, including approximately 1.49 million with vision-affecting glaucoma. Among people aged 65 to 84, approximately 2.46 million were estimated to have glaucoma. This creates a substantial long-term population for trabecular bypass implants, goniotomy devices, canaloplasty systems, drainage implants, cyclophotocoagulation technologies, and other surgical approaches when topical medications or laser therapy are insufficient.

Retinal disease contributes another procedural growth pool. Approximately 9.6 million people in the United States were estimated to have diabetic retinopathy in 2021, creating a large population requiring longitudinal retina management. Although most diabetic retinopathy treatment is nonsurgical, progression to vitreous hemorrhage, tractional retinal detachment, and other advanced complications can create demand for vitrectomy systems, cutters, illumination probes, tamponade products, forceps, laser probes, and other vitreoretinal technologies.

The market is therefore balanced between very high-volume standardized procedures and lower-volume but technologically complex surgery. Cataract cases support enormous recurring IOL and consumable demand. Glaucoma creates a growing implant and microinterventional opportunity. Vitreoretinal procedures support premium capital systems and recurring high-value disposables. Refractive surgery creates demand for excimer and femtosecond laser platforms. Corneal and other anterior-segment procedures provide additional specialty demand.

Over 2026–2035, competition will increasingly revolve around the economics of the entire surgical episode. Buyers will favor technologies that provide predictable refractive outcomes, simplify surgical steps, reduce consumable complexity, improve surgeon control, shorten case time, reduce postoperative interventions, and support premium services where permitted. This creates a market where clinical performance and workflow economics are becoming inseparable.

 

Key Market Drivers: What’s Fueling the U.S. Ophthalmic Surgical Devices Market Boom?

The most powerful underlying driver is the growing number of older Americans. The U.S. population is aging rapidly, and cataract incidence increases substantially with age. At the same time, older patients are more likely to present with multiple ocular conditions, including cataract combined with glaucoma, macular disease, corneal pathology, or diabetic eye disease. This increases both procedure volumes and procedure complexity. A cataract procedure involving astigmatism management, premium lens implantation, femtosecond assistance, or simultaneous glaucoma intervention generates a significantly different device-value profile from conventional cataract extraction alone.

A second major driver is the sheer scale of U.S. cataract surgery. Cataract surgery is among the highest-volume operations performed in the country. The estimated increase from approximately 5.1 million U.S. cataract procedures in 2025 toward 5.9 million around 2030 creates predictable recurring unit demand. Unlike capital-equipment markets that depend largely on replacement cycles, cataract surgery generates revenue every time a lens, tubing set, cassette, viscoelastic, injector, knife, drape, cannula, or procedure-specific disposable is consumed.

A third driver is the increasing economic importance of refractive cataract surgery. Cataract treatment is evolving from simple restoration of visual clarity toward refractive outcome optimization. Patients increasingly discuss astigmatism correction, intermediate vision, near vision, spectacle independence, extended depth of focus, multifocality, and personalized lens selection. This is strengthening demand for toric, multifocal, extended-depth-of-focus, enhanced monofocal, and other premium IOL technologies. The commercial impact extends beyond the lens because premium cataract programs can stimulate investment in advanced biometry, digital marking, surgical guidance, femtosecond lasers, aberrometry, and sophisticated preoperative planning.

A fourth driver is the continued shift toward ambulatory surgical centers. Ophthalmic surgery is highly compatible with the ASC model because many procedures are short, standardized, low-incision, and do not require overnight admission. Ophthalmology’s position as one of the largest single-specialty ASC categories creates a powerful commercial channel for manufacturers. The ASC environment rewards compact capital systems, predictable disposable expenditure, fast setup, high instrument reliability, short cleaning or turnover requirements, and vendor service models capable of minimizing downtime.

A fifth driver is the evolution of glaucoma surgery. Historically, many glaucoma patients remained on escalating topical therapy until disease progression justified trabeculectomy or tube-shunt surgery. The growth of minimally invasive and microincisional approaches has created intermediate surgical options. The U.S. glaucoma population of more than four million people means even incremental expansion of surgical eligibility can create substantial device demand. MIGS has also become commercially important because glaucoma intervention can be integrated with cataract surgery, allowing manufacturers to compete for device value inside an already high-volume surgical episode.

A sixth driver is the sophistication of vitreoretinal surgery. Retina surgeons increasingly use smaller-gauge instrumentation, high-cut-rate vitrectomy, advanced fluidics, chandelier illumination, wide-angle visualization, multifunction probes, digitally assisted visualization, and increasingly specialized instruments for membrane peeling and complex retinal repair. Retina procedures are lower volume than cataract surgery but carry a higher equipment and disposable intensity per case, making vitreoretinal platforms strategically important to diversified ophthalmic companies.

Hospital and ASC capital replacement cycles represent another significant growth lever. Phacoemulsification and vitrectomy consoles, ophthalmic microscopes, lasers, digital visualization platforms, and surgical guidance technologies have multi-year installed-base cycles. Replacement decisions are typically triggered by aging equipment, availability of better fluidics, service costs, obsolescence of handpieces or consumables, surgeon recruitment, integration with new surgical techniques, or vendor-wide contracting decisions. Once a manufacturer secures the capital platform, recurring proprietary consumables can generate revenue for years.

Reimbursement economics are also shaping procurement. Medicare remains a central payer for cataract surgery because of the age profile of the patient population. CMS continues to maintain an explicit ambulatory surgical center payment structure, with annual and quarterly payment-rate updates. Providers therefore model technology adoption against facility reimbursement, physician reimbursement, patient-pay premium services, procedural throughput, and incremental device cost rather than evaluating technology purely on clinical novelty.

Finally, surgeon expectations are rising. Ophthalmic surgery is characterized by extremely small operative fields and low tolerance for inconsistency. Surgeons value stable chamber control, predictable fluidics, precise cutting, ergonomic handpieces, reliable injectors, high-quality optics, minimally traumatic implants, streamlined setup, and rapid conversion between procedures. Manufacturers that deliver reproducibility rather than simply additional features are more likely to achieve durable surgeon loyalty.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in U.S. ophthalmic surgical devices is moving toward procedural integration. The industry’s next competitive phase is less about individual instrument specifications and more about whether the complete system can improve visual outcomes while increasing throughput and reducing workflow friction.

Phacoemulsification remains a major area of technology investment. Manufacturers are refining pump performance, intraocular pressure control, aspiration responsiveness, occlusion management, ultrasound modulation, chamber stability, energy delivery, and handpiece ergonomics. Improvements that reduce surge or unnecessary energy can be clinically meaningful, particularly in dense cataracts, compromised corneas, or complex cases. For high-volume ASCs, automated setup and shorter turnover add an equally important economic benefit.

The FDA granted substantial-equivalence clearance to Alcon’s UNITY VCS and UNITY CS ophthalmic surgical platforms in June 2024, illustrating the ongoing capital-equipment innovation cycle within cataract and vitreoretinal surgery. The introduction of integrated systems is strategically significant because vendors can potentially consolidate previously separate equipment footprints and establish broader consumable relationships with surgical centers.

Intraocular lens innovation is moving rapidly beyond conventional monofocal implants. New lens designs increasingly target intermediate and near vision while attempting to retain distance quality and minimize unwanted optical phenomena. Toric offerings are expanding across premium platforms, while preloaded injectors are becoming important for procedural consistency and handling efficiency. Bausch + Lomb’s enVista Envy and enVista Envy Toric IOLs received U.S. FDA approval in October 2024, adding another presbyopia-correcting platform to the competitive U.S. cataract market.

Johnson & Johnson’s TECNIS PureSee and PureSee Toric II IOLs received an FDA approval covering the TECNIS SIMPLICITY delivery configuration in March 2026. The approval reflects the continuing expansion of extended-depth-of-focus and toric lens options, increasing competitive pressure around optical performance, injector workflow, patient selection, and premium cataract positioning.

Glaucoma surgery is moving toward less invasive interventions, sustained intraocular pressure control, and earlier procedural treatment. Trabecular bypass, goniotomy, canaloplasty, subconjunctival implants, aqueous drainage devices, and cyclophotocoagulation platforms are increasingly differentiated by safety profile, learning curve, ability to combine with cataract surgery, durability, and payer coverage. The availability of multiple approaches means ophthalmic practices are developing increasingly individualized surgical algorithms based on disease stage and target pressure rather than adopting a single universal MIGS technique.

Vitreoretinal technology is evolving through smaller instrument gauges, faster cutters, improved duty cycles, stable pressure management, brighter and safer illumination, multifunction devices, and digital visualization. The direction of innovation is toward reducing instrument exchanges and enabling precise tissue manipulation through smaller incisions. Retina specialists are particularly sensitive to platform ergonomics and visualization because procedural complexity can vary substantially from routine macular surgery to complex diabetic tractional retinal detachment.

Laser-based ophthalmic surgery remains a technologically differentiated category. Femtosecond lasers are used in corneal refractive procedures and selected cataract workflows, while excimer lasers continue to support corneal reshaping. ZEISS received FDA approval for design changes to the VISUMAX 800 femtosecond laser system in January 2024, demonstrating continuing innovation around high-speed refractive laser platforms.

Digital surgical guidance is becoming a strategic layer across all these technologies. Image registration, digital toric alignment, heads-up visualization, intraoperative imaging, electronic surgical planning, cloud-connected equipment, data capture, and AI-supported planning are gradually linking the diagnostic and surgical workflow. The ultimate commercial opportunity is an integrated digital pathway that starts with preoperative measurement and ends with postoperative outcome analysis.

 

Segmentation Insights

The U.S. Ophthalmic Surgical Devices Market is segmented on the basis of product category, surgery type, technology type, end user, and region. These five dimensions reflect the way U.S. manufacturers, distributors, investors, and provider systems evaluate the market.

 

By Product Category

Cataract Surgery Devices and Intraocular Lenses

Cataract devices represent the largest product category by revenue and procedure volume. The segment includes monofocal IOLs, toric IOLs, multifocal and extended-depth-of-focus IOLs, phacoemulsification systems, phaco handpieces, irrigation and aspiration sets, cassettes, IOL injectors, ophthalmic viscoelastic devices, knives, cannulas, capsular devices, and associated disposable procedure packs.

IOLs provide the largest recurring implant opportunity. Standard monofocal lenses create a large stable baseline, while premium IOLs drive disproportionate revenue growth. Increasing patient interest in spectacle independence, astigmatism correction, and intermediate vision is shifting manufacturer competition toward differentiated optical designs and sophisticated patient-selection pathways.

Capital-platform competition is closely linked to IOL strategy. Large ophthalmic companies can use phaco systems, service support, and consumable contracting to strengthen relationships with surgical centers that also purchase their lenses. This portfolio effect makes cataract surgery one of the clearest examples of platform competition within U.S. medtech.

Vitreoretinal Surgery Devices

Vitreoretinal devices include vitrectomy machines, high-speed cutters, illumination systems, laser probes, forceps, scissors, cannulas, trocars, valved entry systems, diathermy instruments, silicone oil and gas delivery accessories, and related disposables.

Growth is being supported by an aging population, diabetic retinal complications, macular disorders, retinal detachment, and increasingly sophisticated surgical treatment. The segment is particularly attractive because capital platforms generate recurring proprietary disposable revenue.

Technology differentiation focuses on cutter speed, fluidics stability, instrument gauge, illumination quality, multifunction capability, and surgeon control. Large retina centers can be highly loyal to established platforms, creating meaningful installed-base barriers for new entrants.

Glaucoma Surgery Devices

The glaucoma surgical device category includes trabecular bypass implants, goniotomy systems, canaloplasty devices, drainage implants, glaucoma shunts, subconjunctival implants, cyclophotocoagulation probes, surgical blades, and related accessories.

The strategic opportunity lies in moving glaucoma intervention earlier in the treatment pathway. Traditional incisional glaucoma surgery remains essential for advanced disease, but minimally invasive alternatives have expanded the addressable patient pool. Cataract surgery provides a particularly important opportunity for combined treatment because glaucoma can be addressed during an already scheduled ophthalmic procedure.

Competition is fragmented relative to cataract, with companies differentiated by mechanism of action, implant design, reimbursement status, standalone versus combination indication, ease of use, and physician training requirements.

Refractive and Corneal Surgery Devices

This segment includes excimer lasers, femtosecond lasers, lenticule-extraction platforms, keratoplasty instruments, trephines, corneal implants, refractive surgical accessories, and devices used in specialty corneal procedures.

Demand is more sensitive to consumer economics than Medicare-dominated cataract surgery because many refractive procedures are self-pay. However, the category remains strategically attractive because premium clinics compete strongly on technology, procedural speed, recovery profile, and patient experience.

Corneal surgery adds a clinically driven component, particularly through keratoplasty and other procedures requiring highly specialized instrumentation. The installed base of refractive lasers also creates recurring service, software, maintenance, and procedure-card revenue opportunities.

Ophthalmic Surgical Instruments, Consumables and Accessories

This category includes forceps, scissors, knives, speculums, cannulas, irrigation systems, disposable packs, sutures, viscoelastic delivery products, microinstruments, drapes, blades, tubing, handpieces, and procedure-specific accessories.

Although individual products may have relatively low selling prices compared with capital systems or implants, their recurring utilization produces a large cumulative revenue opportunity. High-volume ASCs place strong emphasis on standardized procedure packs, supply continuity, low setup complexity, waste reduction, and reliable inventory availability.

The category is more fragmented than capital equipment, creating opportunities for specialized suppliers, private-label manufacturers, and distributors. However, large integrated ophthalmic companies can bundle consumables into capital contracts and thereby defend share.

 

By Surgery Type

Cataract and Refractive Lens Exchange Surgery

Cataract and lens replacement procedures dominate U.S. ophthalmic surgical volumes. Demand is increasingly moving from basic cataract extraction toward refractive cataract surgery in which lens selection, astigmatism management, intraoperative precision, and postoperative spectacle independence influence device selection.

The combination of millions of annual procedures and single-use implants makes cataract surgery the most predictable recurring revenue pool in ophthalmic surgery. Procedure growth is further amplified by the aging population and increasing willingness of patients to pay for premium lens technologies.

Glaucoma Surgery

Glaucoma surgery includes conventional filtration surgery, drainage-device implantation, trabecular and canal-based procedures, cyclophotocoagulation, and minimally invasive glaucoma surgery.

Growth will increasingly depend on whether procedural interventions move earlier in the treatment pathway. Devices that reduce medication dependence while maintaining favorable safety profiles are particularly attractive in older patients who may struggle with adherence to chronic eye-drop regimens.

Vitreoretinal Surgery

Vitrectomy and related retinal procedures form a high-value surgical category. Procedures include retinal detachment repair, macular hole surgery, epiretinal membrane peeling, management of vitreous hemorrhage, diabetic tractional retinal detachment, and selected complex intraocular procedures.

The segment rewards advanced technology because difficult retina cases require precise fluidics, superior visualization, delicate tissue handling, and reliable instruments. Academic and tertiary referral centers remain particularly important early adopters.

Refractive Corneal Surgery

Refractive surgery encompasses LASIK, PRK, small-incision lenticule extraction and related vision-correction procedures. Procedure volume fluctuates with consumer confidence and discretionary spending, but the segment remains technologically influential.

Competitive advantage depends strongly on visual outcomes, treatment speed, flap or lenticule creation precision, ease of workflow, patient recovery, and surgeon familiarity. Capital cost and procedure-specific licensing or consumables also influence provider purchasing.

Corneal, Oculoplastic and Other Ophthalmic Surgery

The remaining surgical market includes corneal transplantation, specialty anterior-segment procedures, ocular trauma repair, selected pediatric ophthalmic surgery, oculoplastic procedures, and other microsurgical interventions.

This category is fragmented but strategically meaningful for manufacturers of specialty instruments, blades, forceps, scissors, implants, tissue-handling systems, and microsurgical accessories. Demand tends to concentrate in academic centers and subspecialty practices.

 

By Technology Type

Phacoemulsification and Advanced Fluidics

Phacoemulsification remains the principal technology used for cataract extraction. Continued improvements in fluidics, vacuum control, ultrasound delivery, chamber stability, handpiece ergonomics, and automation are improving both clinical control and procedural throughput.

The installed base creates significant recurring revenue because proprietary cassettes, tubing, packs, and handpieces are repeatedly consumed or replaced. Consequently, gaining a phaco placement can be economically more important than the initial capital sale.

Femtosecond and Excimer Laser Technologies

Femtosecond technology is used for selected refractive and cataract applications, while excimer lasers remain central to corneal ablation procedures. These systems compete on speed, precision, treatment range, ease of docking, workflow integration, and capital economics.

While laser-assisted cataract surgery remains less universal than conventional phacoemulsification, femtosecond systems can retain strategic value in premium surgical practices with sufficient case density and patient-pay economics.

Microincisional and MIGS Technologies

Microincisional technologies encompass minimally invasive glaucoma devices and surgical techniques designed to reduce tissue disruption, improve recovery, and lower procedural morbidity.

This is expected to remain one of the faster-growing technology areas through 2035 because it expands the range of glaucoma patients who can potentially receive procedural intervention without progressing directly to more invasive filtration surgery.

High-Speed Small-Gauge Vitreoretinal Technology

Small-gauge vitrectomy has transformed retina surgery by enabling smaller incisions and improving postoperative recovery. Technology development is focused on high cutting rates, precise duty cycles, pressure stability, illumination, and multifunction instrumentation.

The market benefits from a combination of premium capital equipment and recurring disposable utilization, producing an attractive installed-base revenue model.

Digital, Image-Guided and Connected Surgical Technology

Digital surgical technology includes image-guided toric alignment, digital microscopes, heads-up displays, data integration, intraoperative imaging, electronic surgical planning, and connected capital equipment.

This is likely to be one of the most strategically important technology layers over the next decade. As ophthalmology becomes increasingly data-driven, companies able to connect diagnostics, planning, surgery, implants, and outcomes can create stronger provider lock-in than companies selling individual devices.

 

By End User

Ambulatory Surgery Centers

ASCs represent the most important end-user growth channel for ophthalmic surgical devices. Ophthalmology already represents approximately one-fifth of single-specialty ASCs billing Medicare, reflecting the suitability of eye surgery for outpatient care.

ASC purchasing decisions emphasize case throughput, consumable cost, room utilization, capital financing, surgeon preference, equipment uptime, and vendor responsiveness. Manufacturers that can demonstrate lower cost per case or faster turnover can win even when acquisition prices are higher.

Hospitals and Integrated Health Systems

Hospitals remain important for complex vitreoretinal procedures, trauma, high-risk patients, pediatric cases, advanced glaucoma surgery, and ophthalmic procedures involving patients with significant medical comorbidities.

Large health systems also exert purchasing leverage through enterprise contracts and centralized value-analysis committees. Vendors must increasingly demonstrate service support, supply-chain resilience, training, standardization opportunities, and total economic value.

Ophthalmic Specialty Clinics

Large ophthalmology groups increasingly operate integrated diagnostic, surgical, and postoperative care models. Groups may own or partner with ASCs, making them influential decision makers across IOLs, glaucoma devices, surgical instrumentation, lasers, and capital equipment.

Practice consolidation is strengthening the negotiating power of high-volume groups and encouraging vendors to offer enterprise-level contracting rather than individual surgeon relationships.

Academic Eye Institutes and Tertiary Referral Centers

Academic centers are disproportionately important for advanced retina, cornea, glaucoma, complex cataract, clinical trials, surgical training, and early technology adoption.

Although their absolute procedure share is lower than community ophthalmology, their influence is substantial because techniques adopted by leading centers can diffuse through fellowship training, publications, congress presentations, and surgeon education.

Office-Based and Specialty Procedure Centers

Selected laser, glaucoma, corneal, and minor ophthalmic procedures are being performed in office-based procedural environments where appropriate.

This channel favors compact equipment, low capital intensity, simplified sterilization, limited staffing requirements, and procedures that can be economically performed outside a full ASC.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. Ophthalmic Surgical Devices Market is geographically segmented into the South, West, Northeast, and Midwest. Regional opportunity is driven by population size, age distribution, cataract surgery volume, ophthalmologist density, ASC infrastructure, Medicare exposure, commercial insurance mix, urban growth, presence of academic eye centers, and willingness to adopt premium refractive technologies.

The South represents the largest regional opportunity, while the West is expected to record the fastest overall growth through 2035. The Northeast remains a premium and clinically sophisticated market, while the Midwest provides a large, stable base of community ophthalmology and academic referral demand.

South

The South represented an estimated USD 2.49 billion in ophthalmic surgical-device revenue in 2025, equivalent to approximately 35.5% of the national market. Assuming continued procedure growth and expansion of premium technologies, the region could exceed USD 5.0 billion by 2035.

The region includes Alabama, Arkansas, Delaware, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, Virginia, and West Virginia, with the District of Columbia also contributing to the broader regional provider ecosystem.

Florida represents one of the most strategically important ophthalmic surgery markets in the country because of its exceptional concentration of older adults. Approximately 5.09 million Florida residents were aged 65 or older in 2024, creating an enormous addressable population for cataract extraction, glaucoma intervention, retinal surgery, and premium IOL adoption.

Florida’s ophthalmic market is supported by dense retirement communities, Medicare exposure, large multisite eye-care groups, ophthalmology-focused ASCs, and major population centers including Miami, Tampa, Orlando, Jacksonville, and Southwest Florida. The state’s surgical-device demand therefore combines high conventional cataract volume with opportunities for premium lenses and glaucoma procedures.

Texas is another critical market because of population scale and its rapidly expanding metropolitan areas. Houston, Dallas-Fort Worth, Austin, and San Antonio support large ophthalmology networks and surgical facilities. Texas also provides a favorable environment for high-throughput ASC models because surgical demand is spread across both established metropolitan centers and fast-growing suburban markets.

North Carolina and Georgia are becoming increasingly important because population growth is expanding the pool of commercially insured and Medicare patients. Charlotte, Raleigh-Durham, Atlanta, and surrounding suburban markets support growing ophthalmic group practices and ASC development. Academic centers in these states also contribute advanced retina, glaucoma, corneal, and complex cataract demand.

Virginia and Maryland contain sophisticated healthcare markets with strong physician networks, large integrated health systems, and proximity to academic and research institutions. These markets are particularly attractive for premium cataract systems, retina platforms, surgical imaging, and new glaucoma technologies.

Tennessee and Kentucky have established ophthalmic referral networks and sizable rural catchment areas. Manufacturers that can support efficient regional surgical centers can capture demand from patients referred from smaller communities into Nashville, Knoxville, Memphis, Louisville, Lexington, and other metropolitan centers.

Alabama, Mississippi, Louisiana, Arkansas, Oklahoma, South Carolina, and West Virginia provide substantial underlying clinical demand but have more uneven specialist and ASC density. Diabetes burden and rural access limitations can increase retinal disease complexity in portions of these states. The opportunity therefore includes not only premium urban surgery centers but scalable equipment and consumables for regional referral facilities.

Delaware represents a smaller absolute market but benefits from an aging population profile. West Virginia also has an older population relative to the national average, creating significant per-capita cataract and glaucoma demand despite its smaller total population.

The South should remain the largest market through 2035 because of its combination of population migration, retiree concentration, ASC expansion, high cataract volumes, diabetes-related retinal disease, and growing ophthalmology group consolidation. The strongest state opportunities are expected in Florida and Texas, followed by North Carolina, Georgia, Virginia, Tennessee, and Maryland.

West

The West represented approximately USD 1.72 billion in 2025 and is expected to become the fastest-growing regional market. Revenue could approach approximately USD 3.7 billion by 2035, supported by population growth, premium technology adoption, strong refractive surgery penetration, medtech innovation, and sophisticated integrated provider networks.

The region includes Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.

California is the dominant state market in the West. Its large population, extensive ophthalmologist base, major academic centers, affluent patient segments, medtech ecosystem, and high density of refractive and premium cataract practices make it one of the most commercially important ophthalmic markets nationally.

Southern California is particularly influential in refractive surgery and premium lens adoption, while Los Angeles, San Diego, Orange County, the Bay Area, Sacramento, and other major markets support substantial cataract, glaucoma, retina, and corneal procedural volumes. California also plays an outsized role in surgeon education and adoption of digital technologies.

Arizona and Nevada are high-growth markets because of rapid population expansion and substantial retiree migration. Phoenix, Scottsdale, Tucson, Las Vegas, and Reno are particularly attractive for cataract and glaucoma technologies. Arizona’s age profile strengthens the recurring cataract opportunity, while both states support patient-pay premium lens and refractive services.

Colorado and Utah have younger population profiles than several other states but benefit from population growth, strong integrated healthcare systems, highly educated patient populations, and active refractive-surgery markets. Utah had the youngest median age among U.S. states in 2024, illustrating why its ophthalmic opportunity differs from retiree-heavy Florida or Arizona: growth is more closely linked to refractive services, population expansion, and long-term procedure demand than immediate geriatric burden.

Washington and Oregon combine large metropolitan markets with strong adoption of technology-enabled healthcare. Seattle and Portland support sophisticated specialty ophthalmology, academic referral care, retina practices, and digitally integrated provider systems. These states are attractive launch markets for equipment emphasizing connectivity and workflow integration.

Idaho, Montana, Wyoming, Alaska, and New Mexico are smaller markets with lower absolute procedure volumes. Their strategic need is access. Regional referral centers, mobile service coverage, equipment reliability, and reduced dependence on complex onsite technical support can therefore be important differentiators.

Hawaii has a smaller population but an older demographic profile and geographic isolation, increasing the importance of local surgical capacity and dependable equipment service.

The West is expected to gain national share because it combines three attractive characteristics: high-value premium ophthalmology in California, fast demographic growth in Arizona and Nevada, and strong adoption of digitally enabled care in Pacific and Mountain states.

Northeast

The Northeast represented approximately USD 1.50 billion in 2025 and is expected to approach approximately USD 2.95 billion by 2035.

The region includes Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont, New Jersey, New York, and Pennsylvania.

New York is the largest ophthalmic surgical market in the Northeast. New York City and its surrounding metropolitan area contain dense ophthalmologist networks, academic medical centers, premium cataract practices, retina specialists, and refractive surgery providers. Upstate markets contribute additional community ophthalmology and regional referral demand.

Massachusetts has an unusually high strategic influence relative to population size because Boston is a major center for ophthalmic research, academic medicine, biotechnology, medical devices, and clinical innovation. Novel glaucoma, retina, corneal, and surgical visualization technologies can gain important clinical validation through the state’s academic ecosystem.

Pennsylvania represents a large and diversified market, with Philadelphia, Pittsburgh, and numerous regional population centers supporting cataract, glaucoma, retina, and corneal surgery. Pennsylvania was among the states where older adults outnumbered children by 2024, underscoring its favorable demographic profile for age-related ophthalmic intervention.

New Jersey combines population density, high commercial insurance penetration, proximity to major academic centers, and significant patient-pay capacity. These factors make it an important premium IOL, refractive, and ASC market.

Connecticut, Rhode Island, New Hampshire, Vermont, and Maine are smaller by population but attractive on a per-capita basis because several have older populations. Maine had the highest median age among states in 2024 at approximately 44.8 years, strengthening long-term demand for cataract and glaucoma treatment.

The Northeast is likely to grow somewhat more slowly than the West because population expansion is less rapid, but its revenue quality remains high. Sophisticated surgeons, academic centers, affluent patient pools, high procedure complexity, and strong willingness to evaluate new technology support premium pricing.

The region is particularly valuable to manufacturers launching new IOLs, glaucoma implants, retina technologies, and digital surgical platforms because adoption at leading Northeast centers can influence physician perceptions nationally.

Midwest

The Midwest accounted for approximately USD 1.30 billion in 2025 and could reach approximately USD 2.6 billion by 2035.

The region includes Illinois, Indiana, Michigan, Ohio, Wisconsin, Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, and South Dakota.

Illinois is the region’s largest ophthalmic device market, anchored by Chicago and its extensive academic and community provider networks. Large ophthalmology groups, surgical centers, and tertiary institutions create significant demand across cataract, glaucoma, retina, corneal, and refractive surgery.

Ohio also has a substantial procedure base and multiple large metropolitan markets including Cleveland, Columbus, and Cincinnati. Major referral centers support complex ophthalmic surgery, while community ASCs generate high cataract procedure volumes.

Michigan provides a significant cataract and retina market around Detroit, Grand Rapids, Ann Arbor, and surrounding areas. Population aging in portions of the state supports stable demand even where population growth is slower than in the Sun Belt.

Minnesota is strategically important because of its medtech heritage and sophisticated integrated-provider environment. Minneapolis–St. Paul supports advanced ophthalmic care and creates opportunities for companies introducing digitally integrated or workflow-oriented technologies.

Wisconsin and Indiana provide strong community ophthalmology markets, with procedure economics favoring efficient ASC-based cataract delivery and standardized equipment platforms.

Missouri, Iowa, Kansas, and Nebraska have significant regional referral structures. Their markets reward manufacturers that can support both metropolitan practices and surgeons serving broad rural catchment areas.

North Dakota and South Dakota represent comparatively small markets but illustrate an important geographic challenge in ophthalmology: specialist access across dispersed populations. Durable equipment, strong technical support, standardized consumables, and regional referral relationships are therefore especially relevant.

Overall, the Midwest will remain a stable and commercially important market. Growth will be less dependent on rapid population migration and more dependent on aging, replacement of installed equipment, procedure migration to ASCs, premium IOL penetration, and expansion of glaucoma and retina technology.

 

Key Market Players

The U.S. Ophthalmic Surgical Devices Competitive Landscape is moderately consolidated at the platform level but highly fragmented across specialty implants, instruments, glaucoma technologies, and consumables.

The strongest competitors increasingly operate across multiple parts of the surgical pathway. Companies with phacoemulsification systems, vitrectomy platforms, IOLs, surgical disposables, and digital technologies can influence both capital purchases and recurring procedure revenue. Specialty companies compete through differentiated glaucoma devices, lasers, corneal technologies, retina instruments, premium lenses, or surgical visualization.

Some of the major and strategically relevant players in the U.S. Ophthalmic Surgical Devices industry include Alcon, Johnson & Johnson Vision, Bausch + Lomb, Carl Zeiss Meditec, Glaukos Corporation, STAAR Surgical, Rayner, HOYA Surgical Optics, Topcon Healthcare, LENSAR, Ziemer Ophthalmic Systems, NIDEK, IRIDEX, New World Medical, Sight Sciences, AbbVie/Allergan, Santen Pharmaceutical, Dutch Ophthalmic Research Center, BVI Medical, Beaver-Visitec International, Geuder AG, Katalyst Surgical, Corza Medical, and Surgical Specialties Corporation.

Alcon holds one of the strongest competitive positions because of its breadth in cataract, vitreoretinal surgery, IOLs, consumables, surgical platforms, and visualization. Installed equipment provides a large recurring consumable base and strengthens cross-selling into IOL portfolios.

Johnson & Johnson Vision is particularly important in intraocular lenses and cataract workflow. Its TECNIS portfolio gives it significant exposure to monofocal, toric, presbyopia-correcting, and extended-depth-of-focus categories.

Bausch + Lomb competes across IOLs, phaco technology, instruments, and surgical consumables. The enVista lens platform and broader surgical portfolio position the company to compete in both standard and premium cataract pathways.

Carl Zeiss Meditec holds a differentiated position in refractive surgery, surgical visualization, and digitally connected ophthalmic workflows. Integration between diagnostic planning and surgical execution represents an important competitive advantage.

Glaukos, Sight Sciences, New World Medical, and other glaucoma-focused companies compete in one of the market’s most innovation-intensive niches. Their growth depends heavily on clinical evidence, surgeon training, procedural coding, reimbursement, and the ability to shift glaucoma treatment earlier.

STAAR Surgical operates in the refractive implant category through phakic IOL technology, while LENSAR, Ziemer, NIDEK, and other laser-system suppliers participate in various refractive and cataract-related technology markets.

DORC and BVI Medical are particularly important in vitreoretinal and ophthalmic surgical instrumentation. Specialized instruments remain a major area where surgeon preference and product quality can override the scale advantages of diversified competitors.

Competitive share through 2035 will depend on installed-base conversions, FDA approvals, clinical evidence, premium lens innovation, ASC contracting, surgeon training, product reliability, disposable supply continuity, service responsiveness, and digital ecosystem integration.

 

Recent Developments

Recent developments demonstrate that U.S. ophthalmic surgery is entering another major equipment and implant innovation cycle.

In June 2024, the FDA cleared Alcon’s UNITY VCS and UNITY CS platforms. The clearance is commercially meaningful because integrated cataract and vitreoretinal systems can reshape capital replacement decisions by allowing providers to evaluate broader procedural capabilities rather than replacing individual legacy consoles.

In October 2024, the FDA approved Bausch + Lomb’s enVista Envy hydrophobic acrylic IOL and enVista Envy Toric IOL. The launch expanded competition in presbyopia-correcting cataract surgery and increased pressure on manufacturers to demonstrate intermediate and near visual performance without sacrificing distance quality.

In January 2024, FDA action covering design changes to ZEISS’s VISUMAX 800 reinforced the continuing equipment cycle in femtosecond refractive surgery. Faster, increasingly integrated laser platforms are important for practices seeking to increase procedure throughput and differentiate premium vision-correction services.

In March 2026, FDA approval covering the TECNIS PureSee and PureSee Toric II lenses with the TECNIS SIMPLICITY delivery system expanded the U.S. extended-depth-of-focus lens landscape. This development strengthens competition among premium cataract manufacturers around optical design, injector convenience, astigmatism correction, and patient selection.

Alcon also continued expansion of its Clareon Vivity Toric range in 2026, with FDA approval covering additional cylindrical powers. Range expansion matters commercially because broader power availability increases the portion of cataract patients addressable with a specific premium lens platform.

Beyond individual approvals, the broader market direction is toward connected surgical ecosystems. Ophthalmic companies are increasingly integrating diagnostic data, lens calculations, digital surgical planning, toric alignment, surgical equipment, implants, and postoperative outcomes.

Glaucoma continues to evolve from a medication-dominated market toward a hybrid medical-procedural model. Growing acceptance of minimally invasive surgery is encouraging comprehensive cataract surgeons to participate more actively in glaucoma treatment, broadening the addressable commercial base beyond fellowship-trained glaucoma specialists.

ASC consolidation is another important market development. Larger ophthalmology groups and ASC operators can aggregate thousands of annual procedures, increasing their leverage in negotiations for IOLs, procedure packs, capital systems, and service contracts. This is gradually shifting purchasing influence away from individual surgeons toward regional or enterprise procurement structures, even though surgeon preference remains unusually important in ophthalmology.

 

Conclusion

The U.S. Ophthalmic Surgical Devices Market Size & Share is positioned to expand from approximately USD 7.01 billion in 2025 to USD 14.25 billion by 2035, representing a projected CAGR of approximately 7.35% during 2026–2035.

The market’s resilience is grounded in unusually strong fundamentals. The U.S. has more than 61 million residents aged 65 and older, millions of annual cataract procedures, a glaucoma population exceeding four million people, a large diabetic retinopathy burden, sophisticated ophthalmic specialists, and one of the world’s most developed ambulatory surgery infrastructures.

Cataract surgery will remain the largest revenue pool, but future value growth will increasingly come from higher-value technologies rather than procedure count alone. Premium IOLs, toric correction, extended-depth-of-focus lenses, advanced phaco fluidics, integrated surgical platforms, preloaded delivery systems, digital guidance, and refractive outcome optimization will increase revenue per cataract procedure.

Glaucoma surgery represents one of the most important strategic expansion opportunities. Broader adoption of microinvasive procedures has created a treatment layer between medication therapy and traditional incisional surgery. Companies that establish clinical evidence, reimbursement support, surgeon training, and compelling long-term pressure-control data can meaningfully expand the surgical market.

Vitreoretinal surgery will remain a high-value technology category because complex retinal disease requires advanced capital platforms and procedure-specific disposable instrumentation. The continued evolution of high-speed cutters, fluidics, illumination, small-gauge entry systems, and digital visualization will sustain replacement and recurring revenue opportunities.

Ambulatory surgery centers will be central to commercial strategy. Ophthalmology is already one of the largest single-specialty ASC categories in the United States. Manufacturers must therefore design products and commercial models around ASC economics: predictable per-case cost, equipment uptime, room turnover, inventory simplicity, service quality, surgeon satisfaction, and capital financing.

Geographically, the South will remain the largest market, led particularly by Florida and Texas, while North Carolina, Georgia, Virginia, and Tennessee provide additional expansion opportunities. The West should record the fastest growth, supported by California’s premium technology market and demographic expansion in Arizona and Nevada. The Northeast will remain a high-value innovation and academic-adoption region, while the Midwest will provide durable procedure demand and a large installed equipment base.

For manufacturers and investors, the market is therefore becoming less about selling individual ophthalmic instruments and more about controlling the surgical workflow. Capital systems influence proprietary consumables. Diagnostic data influence implant selection. IOL portfolios affect patient economics. Digital planning influences surgical execution. Surgeon training affects technology diffusion. ASC contracting determines access to procedure volume.

The companies best positioned through 2035 will be those that can combine clinical precision, superior surgical workflow, recurring consumable economics, broad implant portfolios, strong evidence generation, reliable technical service, reimbursement intelligence, and digital integration.

The central strategic question for clients evaluating the U.S. Ophthalmic Surgical Devices Market is not simply how many ophthalmic surgeries will be performed. It is how much device value will be captured within each procedure, which technologies will become embedded in high-volume ASC workflows, how premium cataract and glaucoma intervention will evolve, and which manufacturers can build the strongest integrated procedural ecosystems around the U.S. ophthalmic surgeon.

 

TABLE OF CONTENT

1. U.S. Ophthalmic Surgical Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Ophthalmic Surgical Device Manufacturers
1.6.2. Intraocular Lens and Implant Manufacturers
1.6.3. Component, Optics and Contract Manufacturing Suppliers
1.6.4. Ambulatory Surgery Centers
1.6.5. Hospitals and Integrated Health Systems
1.6.6. Ophthalmology Practices and Specialty Eye Centers
1.6.7. Academic Eye Institutes and Tertiary Referral Centers
1.6.8. Distributors, Group Purchasing Organizations and Specialty Suppliers
1.6.9. CMS, Commercial Payers, FDA and Clinical Decision-Makers

What this section provides: This section defines the ophthalmic surgical device market boundary, study scope, methodology, assumptions, and stakeholder ecosystem so clients understand how the U.S. market is measured, validated, and differentiated from diagnostic ophthalmic devices and routine vision-care products.

2. U.S. Ophthalmic Surgical Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. U.S. Ophthalmic Surgical Procedure Volume Outlook
2.8. High-Growth Opportunity Areas
2.8.1. Premium and Presbyopia-Correcting Intraocular Lenses
2.8.2. Minimally Invasive Glaucoma Surgery Devices
2.8.3. Advanced Phacoemulsification and Fluidics Platforms
2.8.4. Small-Gauge Vitreoretinal Surgery Platforms
2.8.5. Digital, Image-Guided and Connected Ophthalmic Surgery

What this section provides: This section gives decision-makers a concise view of market size, historical performance, forecast growth, procedure dynamics, technology adoption, competitive intensity, and the highest-value commercial opportunities through 2035.

3. U.S. Ophthalmic Surgical Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Aging U.S. Population and Rising Cataract Surgery Demand
3.1.2. Increasing Cataract and Refractive Lens Exchange Procedure Volumes
3.1.3. Expansion of Premium and Advanced Intraocular Lens Adoption
3.1.4. Growth of Ambulatory Ophthalmic Surgery
3.1.5. Increasing Adoption of Minimally Invasive Glaucoma Surgery
3.1.6. Growing Vitreoretinal Surgical Complexity and Procedure Intensity
3.1.7. Ophthalmic Surgical Platform Replacement and Modernization
3.1.8. Rising Demand for Workflow Efficiency and Procedure Throughput
3.2. Restraints and Their Impact Analysis
3.2.1. High Capital Cost of Advanced Ophthalmic Surgical Platforms
3.2.2. Medicare and Commercial Reimbursement Pressure
3.2.3. Premium IOL Affordability and Patient Out-of-Pocket Costs
3.2.4. Surgeon Learning Curves for New Surgical Technologies
3.2.5. Product Recall, Implant Safety and Post-Market Risk
3.2.6. Ophthalmologist and Retina Specialist Workforce Constraints
3.3. Opportunities and Their Impact Analysis
3.3.1. Premium Cataract and Refractive Cataract Surgery
3.3.2. Earlier Procedural Intervention in Glaucoma
3.3.3. Integrated Cataract and Vitreoretinal Surgical Platforms
3.3.4. Preloaded IOL Delivery and Procedure Simplification
3.3.5. Digital Surgical Guidance and Outcome Optimization
3.3.6. ASC Expansion and Ophthalmology Practice Consolidation
3.3.7. Connected Surgical Equipment and Data-Driven Workflow
3.4. Challenges and Their Impact Analysis
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.7. Ophthalmic ASC Procedure Economics Analysis
3.8. Capital Equipment Replacement Cycle Analysis
3.9. Surgeon Preference and Technology Adoption Analysis

What this section provides: This section explains the clinical, demographic, reimbursement, workflow, capital-procurement, and competitive forces influencing U.S. ophthalmic surgical device demand and identifies the major upside opportunities and execution risks.

4. U.S. Ophthalmic Surgical Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Ophthalmic Implant and Consumable Supply Chain Analysis
4.6. Application & Innovation Landscape
4.7. FDA Regulatory Framework Analysis
4.8. CMS Reimbursement and Coverage Landscape
4.9. Cataract Surgery and ASC Payment Environment
4.10. Premium IOL and Patient-Pay Economics
4.11. Import/Export Restrictions & Tariff Impact
4.12. Government Vision Health and Healthy Aging Initiatives
4.13. Impact of Escalating Geopolitical and Supply-Chain Tensions
4.14. ASC and Hospital Value Analysis Decision Framework
4.15. Impact of Ophthalmology Practice Consolidation
4.16. Digitalization of Ophthalmic Surgical Workflows

What this section provides: This section provides a complete view of the external market environment, including reimbursement, regulation, pricing, implant economics, supply chain, technology adoption, ASC purchasing behavior, and competitive pressures.

5. U.S. Ophthalmic Surgical Devices Market – By Product Category

5.1. Overview
5.1.1. Segment Share Analysis, By Product Category, 2025 & 2035 (%)
5.1.2. Cataract Surgery Devices and Intraocular Lenses
5.1.2.1. Monofocal Intraocular Lenses
5.1.2.2. Toric Intraocular Lenses
5.1.2.3. Multifocal Intraocular Lenses
5.1.2.4. Extended Depth-of-Focus Intraocular Lenses
5.1.2.5. Enhanced Monofocal and Other Premium IOLs
5.1.2.6. Phacoemulsification Systems
5.1.2.7. Phaco Handpieces and Fluidics Systems
5.1.2.8. IOL Injectors and Delivery Systems
5.1.2.9. Ophthalmic Viscoelastic Devices
5.1.2.10. Cataract Procedure Packs and Accessories
5.1.3. Vitreoretinal Surgery Devices
5.1.3.1. Vitrectomy Systems
5.1.3.2. Vitrectomy Cutters
5.1.3.3. Illumination Systems and Light Probes
5.1.3.4. Vitreoretinal Laser Probes
5.1.3.5. Forceps, Scissors and Microinstruments
5.1.3.6. Cannulas, Trocars and Entry Systems
5.1.3.7. Tamponade Delivery and Related Accessories
5.1.4. Glaucoma Surgery Devices
5.1.4.1. Trabecular Bypass Implants
5.1.4.2. Goniotomy Devices
5.1.4.3. Canaloplasty Devices
5.1.4.4. Subconjunctival Glaucoma Implants
5.1.4.5. Glaucoma Drainage Devices and Tube Shunts
5.1.4.6. Cyclophotocoagulation Devices
5.1.4.7. Glaucoma Surgical Accessories
5.1.5. Refractive and Corneal Surgery Devices
5.1.5.1. Excimer Laser Systems
5.1.5.2. Femtosecond Laser Systems
5.1.5.3. Lenticule Extraction Systems
5.1.5.4. Keratoplasty Instruments
5.1.5.5. Corneal Surgical Implants and Devices
5.1.5.6. Refractive Surgery Accessories
5.1.6. Ophthalmic Surgical Instruments, Consumables and Accessories
5.1.6.1. Ophthalmic Knives and Blades
5.1.6.2. Forceps and Scissors
5.1.6.3. Cannulas and Irrigation Instruments
5.1.6.4. Speculums and Retractors
5.1.6.5. Procedure Packs and Drapes
5.1.6.6. Micro-Surgical Instruments
5.1.6.7. Other Ophthalmic Surgical Consumables

What this section provides: This section identifies the ophthalmic surgical device categories generating the highest U.S. revenue contribution, recurring consumable demand, premium pricing opportunities, and strongest growth potential through 2035.

6. U.S. Ophthalmic Surgical Devices Market – By Surgery Type

6.1. Overview
6.1.1. Segment Share Analysis, By Surgery Type, 2025 & 2035 (%)
6.1.2. Cataract and Refractive Lens Exchange Surgery
6.1.2.1. Conventional Cataract Surgery
6.1.2.2. Premium Cataract Surgery
6.1.2.3. Femtosecond Laser-Assisted Cataract Surgery
6.1.2.4. Refractive Lens Exchange
6.1.3. Glaucoma Surgery
6.1.3.1. Minimally Invasive Glaucoma Surgery
6.1.3.2. Trabeculectomy
6.1.3.3. Glaucoma Drainage Implant Surgery
6.1.3.4. Cyclodestructive Procedures
6.1.4. Vitreoretinal Surgery
6.1.4.1. Vitrectomy
6.1.4.2. Retinal Detachment Repair
6.1.4.3. Macular Hole Surgery
6.1.4.4. Epiretinal Membrane Surgery
6.1.4.5. Diabetic Vitreoretinal Surgery
6.1.4.6. Other Complex Retinal Procedures
6.1.5. Refractive Corneal Surgery
6.1.5.1. LASIK
6.1.5.2. PRK
6.1.5.3. Small-Incision Lenticule Extraction
6.1.5.4. Other Corneal Refractive Procedures
6.1.6. Corneal, Oculoplastic and Other Ophthalmic Surgery
6.1.6.1. Corneal Transplantation
6.1.6.2. Keratoplasty Procedures
6.1.6.3. Oculoplastic Surgery
6.1.6.4. Ophthalmic Trauma Surgery
6.1.6.5. Pediatric Ophthalmic Surgery
6.1.6.6. Other Ophthalmic Microsurgical Procedures

What this section provides: This section evaluates demand by surgical procedure, helping clients identify procedure-volume pools, high-value interventions, technology-intensive procedures, and emerging areas of surgical adoption.

7. U.S. Ophthalmic Surgical Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Ambulatory Surgery Centers
7.1.2.1. Single-Specialty Ophthalmology ASCs
7.1.2.2. Multispecialty ASCs
7.1.3. Hospitals and Integrated Health Systems
7.1.3.1. Hospital Outpatient Departments
7.1.3.2. Tertiary and Quaternary Hospitals
7.1.3.3. Integrated Delivery Networks
7.1.4. Ophthalmic Specialty Clinics
7.1.4.1. Multisite Ophthalmology Groups
7.1.4.2. Cataract and Refractive Surgery Centers
7.1.4.3. Retina and Glaucoma Specialty Practices
7.1.5. Academic Eye Institutes and Tertiary Referral Centers
7.1.6. Office-Based and Specialty Procedure Centers

What this section provides: This section explains which U.S. care settings account for ophthalmic surgical device purchasing, procedural volume, capital equipment placement, recurring consumable utilization, and early adoption of premium technologies.

8. U.S. Ophthalmic Surgical Devices Market – By Technology Type

8.1. Overview
8.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)
8.1.2. Phacoemulsification and Advanced Fluidics Technologies
8.1.2.1. Ultrasound Phacoemulsification
8.1.2.2. Active Fluidics Platforms
8.1.2.3. Advanced Aspiration and Vacuum Control
8.1.2.4. Integrated Cataract Surgical Platforms
8.1.3. Femtosecond and Excimer Laser Technologies
8.1.3.1. Cataract Femtosecond Lasers
8.1.3.2. Refractive Femtosecond Lasers
8.1.3.3. Excimer Laser Systems
8.1.3.4. Lenticule Extraction Platforms
8.1.4. Microincisional and MIGS Technologies
8.1.4.1. Trabecular Micro-Bypass Technologies
8.1.4.2. Canal-Based Technologies
8.1.4.3. Goniotomy Technologies
8.1.4.4. Subconjunctival Micro-Shunt Technologies
8.1.5. High-Speed Small-Gauge Vitreoretinal Technologies
8.1.5.1. 23-Gauge Systems
8.1.5.2. 25-Gauge Systems
8.1.5.3. 27-Gauge Systems
8.1.5.4. High-Cut-Rate Vitrectomy Technologies
8.1.5.5. Advanced Illumination and Fluidics
8.1.6. Digital, Image-Guided and Connected Surgical Technologies
8.1.6.1. Digital Surgical Guidance
8.1.6.2. Toric Alignment Systems
8.1.6.3. Heads-Up Digital Visualization
8.1.6.4. Intraoperative Imaging
8.1.6.5. Connected Surgical Equipment
8.1.6.6. AI-Assisted Surgical Planning and Workflow

What this section provides: This section evaluates the technology platforms reshaping ophthalmic surgery, highlighting innovations capable of improving precision, workflow efficiency, procedural outcomes, surgeon adoption, and capital equipment economics.

9. U.S. Ophthalmic Surgical Devices Market: Procedure Economics, ASC & Procurement Landscape

9.1. Overview
9.2. U.S. Ophthalmic ASC Penetration Analysis
9.3. Cataract Procedure Cost and Workflow Economics
9.4. Ophthalmic Surgical Equipment Capital Procurement Model
9.5. Capital Replacement Cycle and Installed Base Analysis
9.6. IOL Procurement, Inventory and Consignment Models
9.7. Ophthalmic Surgical Consumable Contracting
9.8. Group Purchasing Organization Influence
9.9. Distributor and Specialty Supplier Role
9.10. Ophthalmology Group Enterprise Contracting
9.11. CMS Reimbursement Impact on Technology Adoption
9.12. Premium IOL and Patient-Pay Procedure Economics
9.13. Equipment Leasing and Capital Financing Trends
9.14. Service Contract and Equipment Uptime Economics
9.15. ASC Value Analysis and Vendor Selection Framework
9.16. Surgeon Preference Versus Corporate Procurement Influence

What this section provides: This section explains how U.S. ophthalmic surgical technologies are purchased and economically evaluated, including ASC economics, capital budgeting, IOL inventory, reimbursement, enterprise contracting, surgeon preference, and recurring consumable relationships.

10. U.S. Ophthalmic Surgical Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Ophthalmic Surgical Procedure Volume Analysis
10.1.4. Regional Ophthalmologist and Surgical Infrastructure Analysis
10.1.5. Regional ASC Penetration and Capacity Analysis
10.1.6. Regional Medicare and Commercial Payer Dynamics
10.1.7. Regional Premium IOL and Advanced Technology Adoption
10.1.8. Regional Procurement and Competitive Dynamics
10.2. West Region
10.2.1. Regional Overview & Trends
10.2.2. West Region Ophthalmic Surgical Device Key Manufacturers and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Surgery Type, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.8. West Region ASC, Reimbursement & Procurement Dynamics
10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Category, 2021–2035
10.2.9.3. California Market Size and Forecast, By Surgery Type, 2021–2035
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035
10.2.9.5. California Market Size and Forecast, By Technology Type, 2021–2035
10.2.9.6. California Ophthalmic Procedure, ASC & Procurement Outlook
10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Category, 2021–2035
10.2.10.3. Washington Market Size and Forecast, By Surgery Type, 2021–2035
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035
10.2.10.5. Washington Market Size and Forecast, By Technology Type, 2021–2035
10.2.10.6. Washington Ophthalmic Procedure, ASC & Procurement Outlook
10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Category, 2021–2035
10.2.11.3. Arizona Market Size and Forecast, By Surgery Type, 2021–2035
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035
10.2.11.5. Arizona Market Size and Forecast, By Technology Type, 2021–2035
10.2.11.6. Arizona Ophthalmic Procedure, ASC & Procurement Outlook
10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Category, 2021–2035
10.2.12.3. Colorado Market Size and Forecast, By Surgery Type, 2021–2035
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035
10.2.12.5. Colorado Market Size and Forecast, By Technology Type, 2021–2035
10.2.12.6. Colorado Ophthalmic Procedure, ASC & Procurement Outlook
10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Category, 2021–2035
10.2.13.3. Oregon Market Size and Forecast, By Surgery Type, 2021–2035
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035
10.2.13.5. Oregon Market Size and Forecast, By Technology Type, 2021–2035
10.2.13.6. Oregon Ophthalmic Procedure, ASC & Procurement Outlook
10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Category, 2021–2035
10.2.14.3. Utah Market Size and Forecast, By Surgery Type, 2021–2035
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035
10.2.14.5. Utah Market Size and Forecast, By Technology Type, 2021–2035
10.2.14.6. Utah Ophthalmic Procedure, ASC & Procurement Outlook
10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Category, 2021–2035
10.2.15.3. Nevada Market Size and Forecast, By Surgery Type, 2021–2035
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035
10.2.15.5. Nevada Market Size and Forecast, By Technology Type, 2021–2035
10.2.15.6. Nevada Ophthalmic Procedure, ASC & Procurement Outlook
10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Category, 2021–2035
10.2.16.3. New Mexico Market Size and Forecast, By Surgery Type, 2021–2035
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035
10.2.16.5. New Mexico Market Size and Forecast, By Technology Type, 2021–2035
10.2.16.6. New Mexico Ophthalmic Procedure, ASC & Procurement Outlook
10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Category, 2021–2035
10.2.17.3. Idaho Market Size and Forecast, By Surgery Type, 2021–2035
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035
10.2.17.5. Idaho Market Size and Forecast, By Technology Type, 2021–2035
10.2.17.6. Idaho Ophthalmic Procedure, ASC & Procurement Outlook
10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Category, 2021–2035
10.2.18.3. Montana Market Size and Forecast, By Surgery Type, 2021–2035
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035
10.2.18.5. Montana Market Size and Forecast, By Technology Type, 2021–2035
10.2.18.6. Montana Ophthalmic Procedure, ASC & Procurement Outlook
10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Category, 2021–2035
10.2.19.3. Wyoming Market Size and Forecast, By Surgery Type, 2021–2035
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035
10.2.19.5. Wyoming Market Size and Forecast, By Technology Type, 2021–2035
10.2.19.6. Wyoming Ophthalmic Procedure, ASC & Procurement Outlook
10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Category, 2021–2035
10.2.20.3. Alaska Market Size and Forecast, By Surgery Type, 2021–2035
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035
10.2.20.5. Alaska Market Size and Forecast, By Technology Type, 2021–2035
10.2.20.6. Alaska Ophthalmic Procedure, ASC & Procurement Outlook
10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Category, 2021–2035
10.2.21.3. Hawaii Market Size and Forecast, By Surgery Type, 2021–2035
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035
10.2.21.5. Hawaii Market Size and Forecast, By Technology Type, 2021–2035
10.2.21.6. Hawaii Ophthalmic Procedure, ASC & Procurement Outlook
10.3. Northeast Region
10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Ophthalmic Surgical Device Key Manufacturers and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035
10.3.4. Northeast Region Market Size and Forecast, By Product Category, 2021–2035
10.3.5. Northeast Region Market Size and Forecast, By Surgery Type, 2021–2035
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035
10.3.7. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035
10.3.8. Northeast Region ASC, Reimbursement & Procurement Dynamics
10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Category, 2021–2035
10.3.9.3. New York Market Size and Forecast, By Surgery Type, 2021–2035
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035
10.3.9.5. New York Market Size and Forecast, By Technology Type, 2021–2035
10.3.9.6. New York Ophthalmic Procedure, ASC & Procurement Outlook
10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Category, 2021–2035
10.3.10.3. Massachusetts Market Size and Forecast, By Surgery Type, 2021–2035
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035
10.3.10.5. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035
10.3.10.6. Massachusetts Ophthalmic Procedure, ASC & Procurement Outlook
10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Category, 2021–2035
10.3.11.3. New Jersey Market Size and Forecast, By Surgery Type, 2021–2035
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035
10.3.11.5. New Jersey Market Size and Forecast, By Technology Type, 2021–2035
10.3.11.6. New Jersey Ophthalmic Procedure, ASC & Procurement Outlook
10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Category, 2021–2035
10.3.12.3. Pennsylvania Market Size and Forecast, By Surgery Type, 2021–2035
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035
10.3.12.5. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035
10.3.12.6. Pennsylvania Ophthalmic Procedure, ASC & Procurement Outlook
10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Category, 2021–2035
10.3.13.3. Connecticut Market Size and Forecast, By Surgery Type, 2021–2035
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035
10.3.13.5. Connecticut Market Size and Forecast, By Technology Type, 2021–2035
10.3.13.6. Connecticut Ophthalmic Procedure, ASC & Procurement Outlook
10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Category, 2021–2035
10.3.14.3. Maine Market Size and Forecast, By Surgery Type, 2021–2035
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035
10.3.14.5. Maine Market Size and Forecast, By Technology Type, 2021–2035
10.3.14.6. Maine Ophthalmic Procedure, ASC & Procurement Outlook
10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Category, 2021–2035
10.3.15.3. Vermont Market Size and Forecast, By Surgery Type, 2021–2035
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035
10.3.15.5. Vermont Market Size and Forecast, By Technology Type, 2021–2035
10.3.15.6. Vermont Ophthalmic Procedure, ASC & Procurement Outlook
10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Category, 2021–2035
10.3.16.3. New Hampshire Market Size and Forecast, By Surgery Type, 2021–2035
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035
10.3.16.5. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035
10.3.16.6. New Hampshire Ophthalmic Procedure, ASC & Procurement Outlook
10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Category, 2021–2035
10.3.17.3. Rhode Island Market Size and Forecast, By Surgery Type, 2021–2035
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035
10.3.17.5. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035
10.3.17.6. Rhode Island Ophthalmic Procedure, ASC & Procurement Outlook
10.3.18. Delaware
10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Category, 2021–2035
10.3.18.3. Delaware Market Size and Forecast, By Surgery Type, 2021–2035
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035
10.3.18.5. Delaware Market Size and Forecast, By Technology Type, 2021–2035
10.3.18.6. Delaware Ophthalmic Procedure, ASC & Procurement Outlook
10.4. South Region
10.4.1. Regional Overview & Trends
10.4.2. South Region Ophthalmic Surgical Device Key Manufacturers and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035
10.4.4. South Region Market Size and Forecast, By Product Category, 2021–2035
10.4.5. South Region Market Size and Forecast, By Surgery Type, 2021–2035
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035
10.4.7. South Region Market Size and Forecast, By Technology Type, 2021–2035
10.4.8. South Region ASC, Reimbursement & Procurement Dynamics
10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Category, 2021–2035
10.4.9.3. Texas Market Size and Forecast, By Surgery Type, 2021–2035
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035
10.4.9.5. Texas Market Size and Forecast, By Technology Type, 2021–2035
10.4.9.6. Texas Ophthalmic Procedure, ASC & Procurement Outlook
10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Category, 2021–2035
10.4.10.3. Florida Market Size and Forecast, By Surgery Type, 2021–2035
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035
10.4.10.5. Florida Market Size and Forecast, By Technology Type, 2021–2035
10.4.10.6. Florida Ophthalmic Procedure, ASC & Procurement Outlook
10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Category, 2021–2035
10.4.11.3. Georgia Market Size and Forecast, By Surgery Type, 2021–2035
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035
10.4.11.5. Georgia Market Size and Forecast, By Technology Type, 2021–2035
10.4.11.6. Georgia Ophthalmic Procedure, ASC & Procurement Outlook
10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Category, 2021–2035
10.4.12.3. North Carolina Market Size and Forecast, By Surgery Type, 2021–2035
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035
10.4.12.5. North Carolina Market Size and Forecast, By Technology Type, 2021–2035
10.4.12.6. North Carolina Ophthalmic Procedure, ASC & Procurement Outlook
10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Category, 2021–2035
10.4.13.3. Tennessee Market Size and Forecast, By Surgery Type, 2021–2035
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035
10.4.13.5. Tennessee Market Size and Forecast, By Technology Type, 2021–2035
10.4.13.6. Tennessee Ophthalmic Procedure, ASC & Procurement Outlook
10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Category, 2021–2035
10.4.14.3. South Carolina Market Size and Forecast, By Surgery Type, 2021–2035
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035
10.4.14.5. South Carolina Market Size and Forecast, By Technology Type, 2021–2035
10.4.14.6. South Carolina Ophthalmic Procedure, ASC & Procurement Outlook
10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Category, 2021–2035
10.4.15.3. Alabama Market Size and Forecast, By Surgery Type, 2021–2035
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035
10.4.15.5. Alabama Market Size and Forecast, By Technology Type, 2021–2035
10.4.15.6. Alabama Ophthalmic Procedure, ASC & Procurement Outlook
10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Category, 2021–2035
10.4.16.3. Mississippi Market Size and Forecast, By Surgery Type, 2021–2035
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035
10.4.16.5. Mississippi Market Size and Forecast, By Technology Type, 2021–2035
10.4.16.6. Mississippi Ophthalmic Procedure, ASC & Procurement Outlook
10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Category, 2021–2035
10.4.17.3. Louisiana Market Size and Forecast, By Surgery Type, 2021–2035
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035
10.4.17.5. Louisiana Market Size and Forecast, By Technology Type, 2021–2035
10.4.17.6. Louisiana Ophthalmic Procedure, ASC & Procurement Outlook
10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Category, 2021–2035
10.4.18.3. Arkansas Market Size and Forecast, By Surgery Type, 2021–2035
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035
10.4.18.5. Arkansas Market Size and Forecast, By Technology Type, 2021–2035
10.4.18.6. Arkansas Ophthalmic Procedure, ASC & Procurement Outlook
10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Category, 2021–2035
10.4.19.3. Kentucky Market Size and Forecast, By Surgery Type, 2021–2035
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035
10.4.19.5. Kentucky Market Size and Forecast, By Technology Type, 2021–2035
10.4.19.6. Kentucky Ophthalmic Procedure, ASC & Procurement Outlook
10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Category, 2021–2035
10.4.20.3. Oklahoma Market Size and Forecast, By Surgery Type, 2021–2035
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035
10.4.20.5. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035
10.4.20.6. Oklahoma Ophthalmic Procedure, ASC & Procurement Outlook
10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Category, 2021–2035
10.4.21.3. Virginia Market Size and Forecast, By Surgery Type, 2021–2035
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035
10.4.21.5. Virginia Market Size and Forecast, By Technology Type, 2021–2035
10.4.21.6. Virginia Ophthalmic Procedure, ASC & Procurement Outlook
10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Category, 2021–2035
10.4.22.3. Maryland Market Size and Forecast, By Surgery Type, 2021–2035
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035
10.4.22.5. Maryland Market Size and Forecast, By Technology Type, 2021–2035
10.4.22.6. Maryland Ophthalmic Procedure, ASC & Procurement Outlook
10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Category, 2021–2035
10.4.23.3. West Virginia Market Size and Forecast, By Surgery Type, 2021–2035
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035
10.4.23.5. West Virginia Market Size and Forecast, By Technology Type, 2021–2035
10.4.23.6. West Virginia Ophthalmic Procedure, ASC & Procurement Outlook
10.5. Midwest Region
10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Ophthalmic Surgical Device Key Manufacturers and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035
10.5.4. Midwest Region Market Size and Forecast, By Product Category, 2021–2035
10.5.5. Midwest Region Market Size and Forecast, By Surgery Type, 2021–2035
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035
10.5.7. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035
10.5.8. Midwest Region ASC, Reimbursement & Procurement Dynamics
10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Category, 2021–2035
10.5.9.3. Illinois Market Size and Forecast, By Surgery Type, 2021–2035
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035
10.5.9.5. Illinois Market Size and Forecast, By Technology Type, 2021–2035
10.5.9.6. Illinois Ophthalmic Procedure, ASC & Procurement Outlook
10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Category, 2021–2035
10.5.10.3. Ohio Market Size and Forecast, By Surgery Type, 2021–2035
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035
10.5.10.5. Ohio Market Size and Forecast, By Technology Type, 2021–2035
10.5.10.6. Ohio Ophthalmic Procedure, ASC & Procurement Outlook
10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Category, 2021–2035
10.5.11.3. Michigan Market Size and Forecast, By Surgery Type, 2021–2035
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035
10.5.11.5. Michigan Market Size and Forecast, By Technology Type, 2021–2035
10.5.11.6. Michigan Ophthalmic Procedure, ASC & Procurement Outlook
10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Category, 2021–2035
10.5.12.3. Minnesota Market Size and Forecast, By Surgery Type, 2021–2035
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035
10.5.12.5. Minnesota Market Size and Forecast, By Technology Type, 2021–2035
10.5.12.6. Minnesota Ophthalmic Procedure, ASC & Procurement Outlook
10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Category, 2021–2035
10.5.13.3. Indiana Market Size and Forecast, By Surgery Type, 2021–2035
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035
10.5.13.5. Indiana Market Size and Forecast, By Technology Type, 2021–2035
10.5.13.6. Indiana Ophthalmic Procedure, ASC & Procurement Outlook
10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Category, 2021–2035
10.5.14.3. Wisconsin Market Size and Forecast, By Surgery Type, 2021–2035
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035
10.5.14.5. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035
10.5.14.6. Wisconsin Ophthalmic Procedure, ASC & Procurement Outlook
10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Category, 2021–2035
10.5.15.3. Missouri Market Size and Forecast, By Surgery Type, 2021–2035
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035
10.5.15.5. Missouri Market Size and Forecast, By Technology Type, 2021–2035
10.5.15.6. Missouri Ophthalmic Procedure, ASC & Procurement Outlook
10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Category, 2021–2035
10.5.16.3. Iowa Market Size and Forecast, By Surgery Type, 2021–2035
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035
10.5.16.5. Iowa Market Size and Forecast, By Technology Type, 2021–2035
10.5.16.6. Iowa Ophthalmic Procedure, ASC & Procurement Outlook
10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Category, 2021–2035
10.5.17.3. Kansas Market Size and Forecast, By Surgery Type, 2021–2035
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035
10.5.17.5. Kansas Market Size and Forecast, By Technology Type, 2021–2035
10.5.17.6. Kansas Ophthalmic Procedure, ASC & Procurement Outlook
10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Category, 2021–2035
10.5.18.3. Nebraska Market Size and Forecast, By Surgery Type, 2021–2035
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035
10.5.18.5. Nebraska Market Size and Forecast, By Technology Type, 2021–2035
10.5.18.6. Nebraska Ophthalmic Procedure, ASC & Procurement Outlook
10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Category, 2021–2035
10.5.19.3. North Dakota Market Size and Forecast, By Surgery Type, 2021–2035
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035
10.5.19.5. North Dakota Market Size and Forecast, By Technology Type, 2021–2035
10.5.19.6. North Dakota Ophthalmic Procedure, ASC & Procurement Outlook
10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Category, 2021–2035
10.5.20.3. South Dakota Market Size and Forecast, By Surgery Type, 2021–2035
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035
10.5.20.5. South Dakota Market Size and Forecast, By Technology Type, 2021–2035
10.5.20.6. South Dakota Ophthalmic Procedure, ASC & Procurement Outlook

What this section provides: This section delivers detailed regional and state-level analysis across all 50 states, enabling clients to identify cataract and ophthalmic surgery volume hubs, aging-population markets, ASC concentration, premium technology hotspots, competitive intensity, and state-level commercial opportunities.

11. U.S. Ophthalmic Surgical Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Competitive Benchmarking
11.3. Company Positioning Matrix
11.3.1. Leaders
11.3.2. Challengers
11.3.3. Innovators
11.3.4. Emerging and Specialized Players
11.4. Product Portfolio Benchmarking
11.5. Cataract Surgical Platform Competitive Analysis
11.6. Intraocular Lens Competitive Analysis
11.7. Glaucoma Surgical Device Competitive Analysis
11.8. Vitreoretinal Platform Competitive Analysis
11.9. Refractive Laser Competitive Analysis
11.10. Ophthalmic Surgical Instrument Competitive Analysis
11.11. Mergers, Acquisitions and Strategic Partnerships
11.12. FDA Approval and Product Launch Benchmarking
11.13. Company Profiles
11.13.1. Alcon Inc.
11.13.2. Johnson & Johnson Vision
11.13.3. Bausch + Lomb Corporation
11.13.4. Carl Zeiss Meditec AG
11.13.5. Glaukos Corporation
11.13.6. STAAR Surgical Company
11.13.7. HOYA Surgical Optics
11.13.8. Rayner
11.13.9. Topcon Healthcare
11.13.10. LENSAR, Inc.
11.13.11. Ziemer Ophthalmic Systems
11.13.12. NIDEK CO., LTD.
11.13.13. IRIDEX Corporation
11.13.14. New World Medical
11.13.15. Sight Sciences, Inc.
11.13.16. Santen Pharmaceutical Co., Ltd.
11.13.17. BVI Medical
11.13.18. Geuder AG
11.13.19. Katalyst Surgical
11.13.20. Corza Medical
11.13.21. Surgical Specialties Corporation
11.13.22. Rumex International
11.13.23. MicroSurgical Technology
11.13.24. Duckworth & Kent
11.13.25. FCI Ophthalmics

Note: Each company profile will include company overview, ophthalmic surgical device portfolio, U.S. market strategy, installed-base positioning, product pipeline, regulatory updates, partnerships, acquisitions, competitive strengths, and recent developments.

What this section provides: This section gives clients detailed competitor benchmarking, market share visibility, product portfolio positioning, innovation direction, installed-base intelligence, and strategic insight into major ophthalmic surgical device manufacturers.

12. U.S. Ophthalmic Surgical Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Next-Generation Presbyopia-Correcting IOLs
12.2.2. Integrated Cataract and Vitreoretinal Surgical Platforms
12.2.3. Advanced MIGS and Micro-Shunt Technologies
12.2.4. High-Speed and Small-Gauge Vitrectomy
12.2.5. Femtosecond and Lenticule-Based Refractive Surgery
12.2.6. Digital Surgical Guidance and Heads-Up Visualization
12.2.7. AI-Assisted Surgical Planning and Outcome Prediction
12.2.8. Connected Ophthalmic Surgical Ecosystems
12.3. Future Cataract Procedure Volume Outlook
12.4. Future Premium IOL Penetration Outlook
12.5. Future MIGS Adoption Outlook
12.6. Future ASC Migration Outlook
12.7. Emerging Business Trends
12.8. Business Opportunities for Startups and Existing Players
12.9. Investment Prioritization Matrix
12.10. Technology Adoption Curve, 2026–2035

What this section provides: This section prepares clients for future technology shifts, procedure migration, premium implant adoption, new surgical platforms, market-structure changes, and investment opportunities through 2035.

13. U.S. Ophthalmic Surgical Devices Market: Strategic Recommendations

13.1. Recommendations for Ophthalmic Surgical Device Manufacturers
13.2. Recommendations for Intraocular Lens Manufacturers
13.3. Recommendations for Glaucoma Device Companies
13.4. Recommendations for Vitreoretinal Device Manufacturers
13.5. Recommendations for Ambulatory Surgery Centers
13.6. Recommendations for Hospitals and Integrated Health Systems
13.7. Recommendations for Ophthalmology Group Practices
13.8. Recommendations for Investors and Private Equity Firms
13.9. Recommendations for Distributors and Channel Partners
13.10. Recommendations for New Entrants and Startups
13.11. U.S. Go-to-Market Strategy Considerations
13.12. Surgeon Education and KOL Development Strategy
13.13. Product Positioning and Portfolio Expansion Guidance
13.14. ASC Contracting and Installed-Base Expansion Strategy
13.15. Premium Technology Commercialization Strategy

What this section provides: This section converts market intelligence into actionable recommendations for product development, U.S. commercialization, surgeon adoption, ASC contracting, portfolio expansion, investment prioritization, and competitive differentiation.

14. U.S. Ophthalmic Surgical Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Market Estimation Limitation
14.4. Forecasting Limitation
14.5. Legal Disclaimer
14.6. Third-Party Data Disclaimer
14.7. Regulatory and Reimbursement Information Disclaimer

What this section provides: This section clarifies the report’s scope limitations, forecasting assumptions, data-use terms, regulatory information boundaries, third-party data limitations, and legal conditions.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Ophthalmic Surgical Devices Market: Market Definition and Scope
TABLE 3: U.S. Ophthalmic Surgical Devices Market: Research Methodology Framework
TABLE 4: U.S. Ophthalmic Surgical Devices Market: Key Assumptions
TABLE 5: U.S. Ophthalmic Surgical Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Ophthalmic Surgical Devices Market: Stakeholder Analysis
TABLE 7: U.S. Ophthalmic Surgical Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Ophthalmic Surgical Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Ophthalmic Surgical Devices Market: Market Attractiveness Index
TABLE 10: U.S. Ophthalmic Surgical Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Ophthalmic Surgical Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 12: U.S. Ophthalmic Surgical Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 13: U.S. Ophthalmic Surgical Devices Market: Drivers; Impact Analysis
TABLE 14: U.S. Ophthalmic Surgical Devices Market: Restraints; Impact Analysis
TABLE 15: U.S. Ophthalmic Surgical Devices Market: Opportunities; Impact Analysis
TABLE 16: U.S. Ophthalmic Surgical Devices Market: Challenges; Impact Analysis
TABLE 17: U.S. Ophthalmic Surgical Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 18: U.S. Ophthalmic Surgical Devices Market: Clinical Workflow Economics Matrix
TABLE 19: U.S. Ophthalmic Surgical Devices Market: Ophthalmic ASC Procedure Economics Matrix
TABLE 20: U.S. Ophthalmic Surgical Devices Market: Capital Equipment Replacement Cycle Analysis
TABLE 21: U.S. Ophthalmic Surgical Devices Market: Surgeon Preference and Technology Adoption Matrix
TABLE 22: U.S. Ophthalmic Surgical Devices Market: PESTEL Analysis
TABLE 23: U.S. Ophthalmic Surgical Devices Market: Porter’s Five Forces Analysis
TABLE 24: U.S. Ophthalmic Surgical Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 25: U.S. Ophthalmic Surgical Devices Market: Value Chain Analysis
TABLE 26: U.S. Ophthalmic Surgical Devices Market: Supply Chain Analysis
TABLE 27: U.S. Ophthalmic Surgical Devices Market: Ophthalmic Implant and Consumable Supply Chain
TABLE 28: U.S. Ophthalmic Surgical Devices Market: Application & Innovation Landscape
TABLE 29: U.S. Ophthalmic Surgical Devices Market: FDA Regulatory Framework Analysis
TABLE 30: U.S. Ophthalmic Surgical Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 31: U.S. Ophthalmic Surgical Devices Market: Cataract Surgery and ASC Payment Environment
TABLE 32: U.S. Ophthalmic Surgical Devices Market: Premium IOL and Patient-Pay Economics
TABLE 33: U.S. Ophthalmic Surgical Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 34: U.S. Ophthalmic Surgical Devices Market: Government Vision Health and Healthy Aging Initiatives
TABLE 35: U.S. Ophthalmic Surgical Devices Market: Geopolitical and Supply-Chain Risk Impact
TABLE 36: U.S. Ophthalmic Surgical Devices Market: ASC and Hospital Value Analysis Decision Framework
TABLE 37: U.S. Ophthalmic Surgical Devices Market: Product Category Snapshot, 2025
TABLE 38: Segment Dashboard; Definition and Scope, by Product Category
TABLE 39: U.S. Ophthalmic Surgical Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 40: U.S. Ophthalmic Surgical Devices Market: Segment Share Analysis, by Product Category, 2025 & 2035 (%)
TABLE 41: U.S. Ophthalmic Surgical Devices Market: Cataract Surgery Devices and Intraocular Lenses Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 42: U.S. Ophthalmic Surgical Devices Market: Vitreoretinal Surgery Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 43: U.S. Ophthalmic Surgical Devices Market: Glaucoma Surgery Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 44: U.S. Ophthalmic Surgical Devices Market: Refractive and Corneal Surgery Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 45: U.S. Ophthalmic Surgical Devices Market: Ophthalmic Surgical Instruments, Consumables and Accessories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 46: U.S. Ophthalmic Surgical Devices Market: Surgery Type Snapshot, 2025
TABLE 47: Segment Dashboard; Definition and Scope, by Surgery Type
TABLE 48: U.S. Ophthalmic Surgical Devices Market, by Surgery Type, 2021–2035 (US$ Billion)
TABLE 49: U.S. Ophthalmic Surgical Devices Market: Segment Share Analysis, by Surgery Type, 2025 & 2035 (%)
TABLE 50: U.S. Ophthalmic Surgical Devices Market: Cataract and Refractive Lens Exchange Surgery Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: U.S. Ophthalmic Surgical Devices Market: Glaucoma Surgery Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: U.S. Ophthalmic Surgical Devices Market: Vitreoretinal Surgery Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: U.S. Ophthalmic Surgical Devices Market: Refractive Corneal Surgery Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: U.S. Ophthalmic Surgical Devices Market: Corneal, Oculoplastic and Other Ophthalmic Surgery Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 55: U.S. Ophthalmic Surgical Devices Market: End User Snapshot, 2025
TABLE 56: Segment Dashboard; Definition and Scope, by End User
TABLE 57: U.S. Ophthalmic Surgical Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 58: U.S. Ophthalmic Surgical Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 59: U.S. Ophthalmic Surgical Devices Market: Ambulatory Surgery Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: U.S. Ophthalmic Surgical Devices Market: Hospitals and Integrated Health Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: U.S. Ophthalmic Surgical Devices Market: Ophthalmic Specialty Clinics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: U.S. Ophthalmic Surgical Devices Market: Academic Eye Institutes and Tertiary Referral Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: U.S. Ophthalmic Surgical Devices Market: Office-Based and Specialty Procedure Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 64: U.S. Ophthalmic Surgical Devices Market: Technology Type Snapshot, 2025
TABLE 65: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 66: U.S. Ophthalmic Surgical Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 67: U.S. Ophthalmic Surgical Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 68: U.S. Ophthalmic Surgical Devices Market: Phacoemulsification and Advanced Fluidics Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: U.S. Ophthalmic Surgical Devices Market: Femtosecond and Excimer Laser Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: U.S. Ophthalmic Surgical Devices Market: Microincisional and MIGS Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: U.S. Ophthalmic Surgical Devices Market: High-Speed Small-Gauge Vitreoretinal Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: U.S. Ophthalmic Surgical Devices Market: Digital, Image-Guided and Connected Surgical Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 73: U.S. Ophthalmic Surgical Devices Market: Procedure Economics and Procurement Snapshot, 2025
TABLE 74: U.S. Ophthalmic Surgical Devices Market: Ophthalmic ASC Penetration Analysis
TABLE 75: U.S. Ophthalmic Surgical Devices Market: Cataract Procedure Cost and Workflow Economics
TABLE 76: U.S. Ophthalmic Surgical Devices Market: Capital Equipment Procurement Model
TABLE 77: U.S. Ophthalmic Surgical Devices Market: Capital Replacement Cycle and Installed Base Analysis
TABLE 78: U.S. Ophthalmic Surgical Devices Market: IOL Procurement, Inventory and Consignment Models
TABLE 79: U.S. Ophthalmic Surgical Devices Market: Surgical Consumable Contracting Analysis
TABLE 80: U.S. Ophthalmic Surgical Devices Market: GPO and Distributor Influence Analysis
TABLE 81: U.S. Ophthalmic Surgical Devices Market: Ophthalmology Group Enterprise Contracting
TABLE 82: U.S. Ophthalmic Surgical Devices Market: CMS Reimbursement Impact on Technology Adoption
TABLE 83: U.S. Ophthalmic Surgical Devices Market: Equipment Leasing, Service Contract and Uptime Economics
TABLE 84: U.S. Ophthalmic Surgical Devices Market: Surgeon Preference versus Corporate Procurement Influence
TABLE 85: U.S. Ophthalmic Surgical Devices Market: Regional Snapshot, 2025
TABLE 86: Segment Dashboard; Definition and Scope, by Geography
TABLE 87: U.S. Ophthalmic Surgical Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 88: U.S. Ophthalmic Surgical Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 89: West Region U.S. Ophthalmic Surgical Devices Market: Regional Overview and Trends
TABLE 90: West Region U.S. Ophthalmic Surgical Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 91: West Region U.S. Ophthalmic Surgical Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 92: West Region U.S. Ophthalmic Surgical Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 93: West Region U.S. Ophthalmic Surgical Devices Market, by Surgery Type, 2021–2035 (US$ Billion)
TABLE 94: West Region U.S. Ophthalmic Surgical Devices Market, by End User and Technology Type, 2021–2035 (US$ Billion)
TABLE 95: California Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 96: Washington Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 97: Arizona Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 98: Colorado Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: Oregon Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 100: Utah Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: Nevada Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 102: New Mexico Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 103: Idaho Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 104: Montana Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 105: Wyoming Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 106: Alaska Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 107: Hawaii Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Northeast Region U.S. Ophthalmic Surgical Devices Market: Regional Overview and Trends
TABLE 109: Northeast Region U.S. Ophthalmic Surgical Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 110: Northeast Region U.S. Ophthalmic Surgical Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 111: Northeast Region U.S. Ophthalmic Surgical Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 112: Northeast Region U.S. Ophthalmic Surgical Devices Market, by Surgery Type, 2021–2035 (US$ Billion)
TABLE 113: Northeast Region U.S. Ophthalmic Surgical Devices Market, by End User and Technology Type, 2021–2035 (US$ Billion)
TABLE 114: New York Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 115: Massachusetts Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 116: New Jersey Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 117: Pennsylvania Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 118: Connecticut Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 119: Maine Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 120: Vermont Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 121: New Hampshire Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: Rhode Island Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: Delaware Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 124: South Region U.S. Ophthalmic Surgical Devices Market: Regional Overview and Trends
TABLE 125: South Region U.S. Ophthalmic Surgical Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 126: South Region U.S. Ophthalmic Surgical Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 127: South Region U.S. Ophthalmic Surgical Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 128: South Region U.S. Ophthalmic Surgical Devices Market, by Surgery Type, 2021–2035 (US$ Billion)
TABLE 129: South Region U.S. Ophthalmic Surgical Devices Market, by End User and Technology Type, 2021–2035 (US$ Billion)
TABLE 130: Texas Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 131: Florida Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 132: Georgia Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 133: North Carolina Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 134: Tennessee Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 135: South Carolina Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 136: Alabama Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 137: Mississippi Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 138: Louisiana Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 139: Arkansas Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 140: Kentucky Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 141: Oklahoma Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 142: Virginia Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Maryland Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: West Virginia Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 145: Midwest Region U.S. Ophthalmic Surgical Devices Market: Regional Overview and Trends
TABLE 146: Midwest Region U.S. Ophthalmic Surgical Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 147: Midwest Region U.S. Ophthalmic Surgical Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 148: Midwest Region U.S. Ophthalmic Surgical Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 149: Midwest Region U.S. Ophthalmic Surgical Devices Market, by Surgery Type, 2021–2035 (US$ Billion)
TABLE 150: Midwest Region U.S. Ophthalmic Surgical Devices Market, by End User and Technology Type, 2021–2035 (US$ Billion)
TABLE 151: Illinois Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 152: Ohio Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 153: Michigan Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 154: Minnesota Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 155: Indiana Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 156: Wisconsin Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 157: Missouri Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 158: Iowa Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 159: Kansas Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 160: Nebraska Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 161: North Dakota Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 162: South Dakota Ophthalmic Surgical Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 163: U.S. Ophthalmic Surgical Devices Market: Competitive Landscape Snapshot, 2025
TABLE 164: U.S. Ophthalmic Surgical Devices Market: Key Company Market Share Analysis, 2025
TABLE 165: U.S. Ophthalmic Surgical Devices Market: Company Positioning Matrix
TABLE 166: U.S. Ophthalmic Surgical Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 167: U.S. Ophthalmic Surgical Devices Market: Cataract and IOL Competitive Benchmarking
TABLE 168: U.S. Ophthalmic Surgical Devices Market: Glaucoma, Vitreoretinal and Refractive Platform Benchmarking
TABLE 169: U.S. Ophthalmic Surgical Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 170: Alcon Inc.: Company Profile
TABLE 171: Johnson & Johnson Vision: Company Profile
TABLE 172: Bausch + Lomb Corporation: Company Profile
TABLE 173: Carl Zeiss Meditec AG: Company Profile
TABLE 174: Glaukos Corporation: Company Profile
TABLE 175: STAAR Surgical Company: Company Profile
TABLE 176: HOYA Surgical Optics: Company Profile
TABLE 177: Rayner: Company Profile
TABLE 178: Topcon Healthcare: Company Profile
TABLE 179: LENSAR, Inc.: Company Profile
TABLE 180: Ziemer Ophthalmic Systems: Company Profile
TABLE 181: NIDEK CO., LTD.: Company Profile
TABLE 182: IRIDEX Corporation: Company Profile
TABLE 183: New World Medical: Company Profile
TABLE 184: Sight Sciences, Inc.: Company Profile
TABLE 185: Santen Pharmaceutical Co., Ltd.: Company Profile
TABLE 186: BVI Medical: Company Profile
TABLE 187: Geuder AG: Company Profile
TABLE 188: Katalyst Surgical: Company Profile
TABLE 189: Corza Medical: Company Profile
TABLE 190: Surgical Specialties Corporation: Company Profile
TABLE 191: Rumex International: Company Profile
TABLE 192: MicroSurgical Technology: Company Profile
TABLE 193: Duckworth & Kent: Company Profile
TABLE 194: FCI Ophthalmics: Company Profile
TABLE 195: U.S. Ophthalmic Surgical Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 196: U.S. Ophthalmic Surgical Devices Market: Disruptive Technologies Impact Matrix
TABLE 197: U.S. Ophthalmic Surgical Devices Market: Future Cataract Procedure Volume Outlook
TABLE 198: U.S. Ophthalmic Surgical Devices Market: Future Premium IOL Penetration Outlook
TABLE 199: U.S. Ophthalmic Surgical Devices Market: Future MIGS Adoption Outlook
TABLE 200: U.S. Ophthalmic Surgical Devices Market: Future ASC Migration Outlook
TABLE 201: U.S. Ophthalmic Surgical Devices Market: Emerging Business Trends
TABLE 202: U.S. Ophthalmic Surgical Devices Market: Investment Prioritization Matrix
TABLE 203: U.S. Ophthalmic Surgical Devices Market: Strategic Recommendations for Device Manufacturers
TABLE 204: U.S. Ophthalmic Surgical Devices Market: Strategic Recommendations for Ambulatory Surgery Centers and Health Systems
TABLE 205: U.S. Ophthalmic Surgical Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 206: U.S. Ophthalmic Surgical Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 207: U.S. Ophthalmic Surgical Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 208: U.S. Ophthalmic Surgical Devices Market: Go-to-Market Strategy Considerations
TABLE 209: U.S. Ophthalmic Surgical Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 210: U.S. Ophthalmic Surgical Devices Market: Scope Limitation
TABLE 211: U.S. Ophthalmic Surgical Devices Market: Data Use Limitation
TABLE 212: U.S. Ophthalmic Surgical Devices Market: Market Estimation Limitation
TABLE 213: U.S. Ophthalmic Surgical Devices Market: Forecasting Limitation
TABLE 214: U.S. Ophthalmic Surgical Devices Market: Legal Disclaimer
TABLE 215: U.S. Ophthalmic Surgical Devices Market: Third-Party Data Disclaimer
TABLE 216: U.S. Ophthalmic Surgical Devices Market: Regulatory and Reimbursement Information Disclaimer

List of Figures

FIGURE 1: U.S. Ophthalmic Surgical Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: U.S. Ophthalmic Surgical Devices Market Ecosystem
FIGURE 4: Stakeholder Ecosystem
FIGURE 5: Market Attractiveness Analysis
FIGURE 6: U.S. Ophthalmic Surgical Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 7: U.S. Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 8: U.S. Ophthalmic Surgical Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 9: U.S. Ophthalmic Surgical Devices Market Dynamics
FIGURE 10: Innovation & Patent Landscape, 2021–2025
FIGURE 11: Clinical Workflow Economics Framework
FIGURE 12: Ophthalmic ASC Procedure Economics Framework
FIGURE 13: Capital Equipment Replacement Cycle
FIGURE 14: Surgeon Preference and Technology Adoption Framework
FIGURE 15: PESTEL Analysis
FIGURE 16: Porter’s Five Forces Analysis
FIGURE 17: Value Chain Analysis
FIGURE 18: Supply Chain Analysis
FIGURE 19: FDA Regulatory and CMS Reimbursement Framework
FIGURE 20: Premium IOL and Patient-Pay Economics Framework
FIGURE 21: ASC and Hospital Value Analysis Decision Framework
FIGURE 22: Digitalization of Ophthalmic Surgical Workflows
FIGURE 23: Product Category Segment Market Share Analysis, 2025 & 2035
FIGURE 24: Product Category Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: Cataract Surgery Devices and Intraocular Lenses Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 26: Vitreoretinal Surgery Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 27: Glaucoma Surgery Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 28: Refractive and Corneal Surgery Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 29: Ophthalmic Surgical Instruments, Consumables and Accessories Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 30: Surgery Type Segment Market Share Analysis, 2025 & 2035
FIGURE 31: Surgery Type Segment Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 32: Cataract and Refractive Lens Exchange Surgery Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 33: Glaucoma Surgery Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 34: Vitreoretinal Surgery Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 35: Refractive Corneal Surgery Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 36: Corneal, Oculoplastic and Other Ophthalmic Surgery Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 37: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 38: End User Segment Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 39: Ambulatory Surgery Centers Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 40: Hospitals and Integrated Health Systems Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 41: Ophthalmic Specialty Clinics Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 42: Academic Eye Institutes and Tertiary Referral Centers Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 43: Office-Based and Specialty Procedure Centers Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 44: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 45: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 46: Phacoemulsification and Advanced Fluidics Technologies Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 47: Femtosecond and Excimer Laser Technologies Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 48: Microincisional and MIGS Technologies Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 49: High-Speed Small-Gauge Vitreoretinal Technologies Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 50: Digital, Image-Guided and Connected Surgical Technologies Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 51: U.S. Ophthalmic ASC Penetration and Procedure Migration Trend
FIGURE 52: Cataract Procedure Cost and Workflow Economics Framework
FIGURE 53: Capital Equipment Procurement and Installed Base Framework
FIGURE 54: IOL Procurement, Inventory and Consignment Model
FIGURE 55: CMS Reimbursement Impact on Technology Adoption
FIGURE 56: Surgeon Preference versus Corporate Procurement Framework
FIGURE 57: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 58: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: West Region U.S. Ophthalmic Surgical Devices Market Share and Leading Players, 2025
FIGURE 60: West Region Market Share Analysis by State, 2025
FIGURE 61: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: California Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Washington Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Arizona Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Colorado Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Oregon Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Utah Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Nevada Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: New Mexico Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Idaho Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Montana Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Wyoming Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: Alaska Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Hawaii Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: Northeast Region U.S. Ophthalmic Surgical Devices Market Share and Leading Players, 2025
FIGURE 76: Northeast Region Market Share Analysis by State, 2025
FIGURE 77: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: New York Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Massachusetts Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: New Jersey Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: Pennsylvania Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Connecticut Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: Maine Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: Vermont Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: New Hampshire Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Rhode Island Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Delaware Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: South Region U.S. Ophthalmic Surgical Devices Market Share and Leading Players, 2025
FIGURE 89: South Region Market Share Analysis by State, 2025
FIGURE 90: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Texas Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: Florida Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Georgia Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: North Carolina Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Tennessee Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: South Carolina Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Alabama Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Mississippi Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Louisiana Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Arkansas Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Kentucky Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Oklahoma Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Virginia Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Maryland Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: West Virginia Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Midwest Region U.S. Ophthalmic Surgical Devices Market Share and Leading Players, 2025
FIGURE 107: Midwest Region Market Share Analysis by State, 2025
FIGURE 108: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Illinois Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Ohio Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Michigan Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: Minnesota Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Indiana Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Wisconsin Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: Missouri Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Iowa Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 117: Kansas Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 118: Nebraska Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 119: North Dakota Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 120: South Dakota Ophthalmic Surgical Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 121: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 122: Company Positioning Matrix
FIGURE 123: Key Player Product Portfolio Benchmarking
FIGURE 124: Cataract and IOL Competitive Landscape
FIGURE 125: Glaucoma Surgical Device Competitive Landscape
FIGURE 126: Vitreoretinal and Refractive Platform Competitive Landscape
FIGURE 127: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 128: U.S. Ophthalmic Surgical Device Innovation Roadmap
FIGURE 129: Future Market Scenario Analysis, 2026–2035
FIGURE 130: Disruptive Technologies Impact Matrix
FIGURE 131: Premium IOL Adoption Roadmap
FIGURE 132: MIGS Adoption Roadmap
FIGURE 133: Advanced Vitreoretinal Technology Opportunity Map
FIGURE 134: Digital Ophthalmic Surgery Growth Roadmap
FIGURE 135: Future ASC Migration Outlook
FIGURE 136: Investment Prioritization Matrix
FIGURE 137: Strategic Growth Roadmap for U.S. Ophthalmic Surgical Device Companies
FIGURE 138: Go-to-Market Strategy Framework
FIGURE 139: Product Positioning and Portfolio Expansion Framework
FIGURE 140: ASC Contracting and Installed-Base Expansion Framework
FIGURE 141: Report Scope and Disclaimer Framework